Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))

Justin Harold; Stefania Bellone; Diego D. Manavell; Levent Mutlu; Blair McNamara; Tobias Max Philipp Hartwich; Margherita Zipponi; Yang Yang-Hartwich; Cem Demirkiran; Miguel Skyler Z. Verzosa; Jungmin Choi; Weilai Dong; Natalia Buza; Pei Hui; Gary Altwerger; Gloria S. Huang; Vaagn Andikyan; Mitchell Clark; Elena Ratner; Masoud Azodi; Peter E. Schwartz; Alessandro D. Santin

doi:10.1016/j.ygyno.2023.01.029

Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))

Justin Harold, Stefania Bellone, Diego D. Manavell, Levent Mutlu, Blair McNamara, Tobias Max Philipp Hartwich, Margherita Zipponi, Yang Yang-Hartwich, Cem Demirkiran, Miguel Skyler Z. Verzosa, Jungmin Choi, Weilai Dong, Natalia Buza, Pei Hui, Gary Altwerger, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Elena Ratner, Masoud AzodiPeter E. Schwartz, Alessandro D. Santin

Department of Biomedical Sciences

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret that Dr Miguel Skyler Z. Verzosa was not tagged correctly in the original order of authors. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	334
Number of pages	1
Journal	Gynecologic Oncology
Volume	170
DOIs	https://doi.org/10.1016/j.ygyno.2023.01.029
Publication status	Published - 2023 Mar

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Inc.

ASJC Scopus subject areas

Oncology
Obstetrics and Gynaecology

Access to Document

10.1016/j.ygyno.2023.01.029

Fingerprint

Dive into the research topics of 'Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))'. Together they form a unique fingerprint.

Cite this

Harold, J., Bellone, S., Manavell, D. D., Mutlu, L., McNamara, B., Hartwich, T. M. P., Zipponi, M., Yang-Hartwich, Y., Demirkiran, C., Verzosa, M. S. Z., Choi, J., Dong, W., Buza, N., Hui, P., Altwerger, G., Huang, G. S., Andikyan, V., Clark, M., Ratner, E., ... Santin, A. D. (2023). Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014)). Gynecologic Oncology, 170, 334. https://doi.org/10.1016/j.ygyno.2023.01.029

Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014)). / Harold, Justin; Bellone, Stefania; Manavell, Diego D. et al.
In: Gynecologic Oncology, Vol. 170, 03.2023, p. 334.

Research output: Contribution to journal › Comment/debate › peer-review

Harold, J, Bellone, S, Manavell, DD, Mutlu, L, McNamara, B, Hartwich, TMP, Zipponi, M, Yang-Hartwich, Y, Demirkiran, C, Verzosa, MSZ, Choi, J, Dong, W, Buza, N, Hui, P, Altwerger, G, Huang, GS, Andikyan, V, Clark, M, Ratner, E, Azodi, M, Schwartz, PE & Santin, AD 2023, 'Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))', Gynecologic Oncology, vol. 170, pp. 334. https://doi.org/10.1016/j.ygyno.2023.01.029

Harold J, Bellone S, Manavell DD, Mutlu L, McNamara B, Hartwich TMP et al. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014)). Gynecologic Oncology. 2023 Mar;170:334. doi: 10.1016/j.ygyno.2023.01.029

@article{ac54dd757cbc49c28520305f6dd7d8d7,

title = "Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))",

abstract = "The authors regret that Dr Miguel Skyler Z. Verzosa was not tagged correctly in the original order of authors. The authors would like to apologise for any inconvenience caused.",

author = "Justin Harold and Stefania Bellone and Manavell, {Diego D.} and Levent Mutlu and Blair McNamara and Hartwich, {Tobias Max Philipp} and Margherita Zipponi and Yang Yang-Hartwich and Cem Demirkiran and Verzosa, {Miguel Skyler Z.} and Jungmin Choi and Weilai Dong and Natalia Buza and Pei Hui and Gary Altwerger and Huang, {Gloria S.} and Vaagn Andikyan and Mitchell Clark and Elena Ratner and Masoud Azodi and Schwartz, {Peter E.} and Santin, {Alessandro D.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = mar,

doi = "10.1016/j.ygyno.2023.01.029",

language = "English",

volume = "170",

pages = "334",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))

AU - Harold, Justin

AU - Bellone, Stefania

AU - Manavell, Diego D.

AU - Mutlu, Levent

AU - McNamara, Blair

AU - Hartwich, Tobias Max Philipp

AU - Zipponi, Margherita

AU - Yang-Hartwich, Yang

AU - Demirkiran, Cem

AU - Verzosa, Miguel Skyler Z.

AU - Choi, Jungmin

AU - Dong, Weilai

AU - Buza, Natalia

AU - Hui, Pei

AU - Altwerger, Gary

AU - Huang, Gloria S.

AU - Andikyan, Vaagn

AU - Clark, Mitchell

AU - Ratner, Elena

AU - Azodi, Masoud

AU - Schwartz, Peter E.

AU - Santin, Alessandro D.

PY - 2023/3

Y1 - 2023/3

N2 - The authors regret that Dr Miguel Skyler Z. Verzosa was not tagged correctly in the original order of authors. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that Dr Miguel Skyler Z. Verzosa was not tagged correctly in the original order of authors. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85149873957&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2023.01.029

DO - 10.1016/j.ygyno.2023.01.029

M3 - Comment/debate

C2 - 36906375

AN - SCOPUS:85149873957

SN - 0090-8258

VL - 170

SP - 334

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -

Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this